Merck: Spinoff Organon Expected To Drive Sustainable Growth

Drug major Merck (MRK) announced Monday that its spinoff Organon is expected to drive sustainable growth and shareholder value as a standalone company focused on women's health.

The initial portfolio of Organon, which will be launched on June 3 as a new company, is expected to generate low to mid-single organic revenue growth off of a 2021 base. At launch, Organon's portfolio will consist of more than 60 medicines and products across its three core franchises: Women's Health, Biosimilars and Established Brands.

Merck is hosting Organon Investor Day today, detailing plans with solid growth opportunities and the ability to make an impact in women's health.

Rob Davis, president, Merck, said, "The spinoff of Organon will help Merck become a leaner, more focused and agile company with stronger growth, and will enable significant operating efficiencies."

Organon is expected to have a global footprint with significant scale and geographic reach, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT